Researcher
Mourad Gumusboga
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Jan 2003 → Today
Projects
1 - 2 of 2 results
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without creating more?From1 Oct 2018 → Today
- Institutional strengthening of the Mycobacteria Reference Laboratory (LRM, Bénin) for quality services and better quality of health care for Mycobacteria and other clinical bacteria, at National and Regional Level.From1 Jan 2018 → 31 Dec 2018
Publications
1 - 10 of 20 results
- Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Authors: A.K.J. Maug, M A Hossain, G Mourad, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pages: 84-86Number of pages: 3 - The simple direct slide method is comparable to indirect Lowenstein Jensen proportion culture for detecting rifampicin resistant tuberculosis(2021)
Authors: Beatrice Achan, Benon B. Asiimwe, Moses L Joloba, G Mourad, Willy Ssengooba, Freddie Bwanga
Number of pages: 5 - Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: nationwide programmatic achievements(2020)
Authors: Alberto Piubello, Mahamadou Bassirou Souleymane, Souleymane Hassane-Harouna, Abdourahamane Yacouba, Pauline Lempens, Mourtala Mohamed Assao-Neino, Ibrahim Maman-Lawan, Sala Attaher, Boubacar Moustapha, Alphazazi Soumana, et al.
Number of pages: 9 - First-line tuberculosis treatment with double-dose rifampicin is well tolerated(2020)
Authors: A.K.J. Maug, M A Hossain, G Mourad, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, Diana Arango, Céline Schurmans, Natacha Herssens, et al.
Pages: 499-505Number of pages: 7 - Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes(2020)
Authors: Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Cécile Uwizeye, G Mourad, Tine Demeulenaere, Nimer Ortuno-Gutierrez, Bouke C de Jong, Armand Van Deun
Number of pages: 11 - Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance(2019)
Authors: Gabriela Torrea, Kamela Charmaine Sy Ng, A Van Deun, Emmanuel André, Justine Kaisergruber, Willy Ssengooba, Christel Desmaretz, Siemon Gabriëls, Michèle Driesen, Maren Diels, et al.
Number of pages: 9 - Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring(2018)
Authors: A Van Deun, K J M Aung, M A Hossain, M. A. H. Salim, G Mourad, Bouke C de Jong, Tom Decroo
Pages: 1450-1461Number of pages: 13 - Specific gyrA gene mutations predict poor treatment outcome in MDR-TB(2016)
Authors: L Rigouts, Nele Coeck, G Mourad, P De Rijk, K J M Aung, M A Hossain, K Fissette, H L Rieder, Conor J. Meehan, Bouke C de Jong, et al.
Pages: 314-323Number of pages: 10 - Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients(2015)
Authors: A Van Deun, K J M Aung, A Hossain, P De Rijk, G Mourad, L Rigouts, Bouke C de Jong
Pages: 185-190Number of pages: 6 - An operational study comparing microscopes and staining variations for tuberculosis LED FM(2014)
Authors: A Van Deun, K J M Aung, M H Khan, Bouke C de Jong, G Mourad, M A Hossain
Pages: 964-971Number of pages: 8